Taipei Exchange - Delayed Quote TWD

TCM Biotech International Corp. (4169.TWO)

55.80
-0.70
(-1.24%)
At close: 2:54:32 PM GMT+8
Loading Chart for 4169.TWO
  • Previous Close 56.50
  • Open 56.50
  • Bid 54.80 x --
  • Ask 55.80 x --
  • Day's Range 54.10 - 56.50
  • 52 Week Range 43.65 - 63.60
  • Volume 32,790
  • Avg. Volume 91,310
  • Market Cap (intraday) 3.295B
  • Beta (5Y Monthly) -0.26
  • PE Ratio (TTM) 155.00
  • EPS (TTM) 0.36
  • Earnings Date --
  • Forward Dividend & Yield 0.29 (0.51%)
  • Ex-Dividend Date Aug 28, 2024
  • 1y Target Est 113.00

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company's products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.

www.tcmbio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4169.TWO

View More

Performance Overview: 4169.TWO

Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4169.TWO
3.63%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.97%

1-Year Return

4169.TWO
1.44%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.11%

3-Year Return

4169.TWO
97.65%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
30.44%

5-Year Return

4169.TWO
136.01%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
88.69%

Compare To: 4169.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4169.TWO

View More

Valuation Measures

Annual
As of 6/5/2025
  • Market Cap

    3.33B

  • Enterprise Value

    2.85B

  • Trailing P/E

    156.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.94

  • Price/Book (mrq)

    3.14

  • Enterprise Value/Revenue

    4.27

  • Enterprise Value/EBITDA

    56.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.15%

  • Return on Assets (ttm)

    0.53%

  • Return on Equity (ttm)

    1.99%

  • Revenue (ttm)

    666.53M

  • Net Income Avi to Common (ttm)

    21.01M

  • Diluted EPS (ttm)

    0.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    532.98M

  • Total Debt/Equity (mrq)

    4.10%

  • Levered Free Cash Flow (ttm)

    146.85M

Research Analysis: 4169.TWO

View More

Company Insights: 4169.TWO

Research Reports: 4169.TWO

View More

People Also Watch